ANTH has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANTH has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Anthera Pharmaceuticals's share price for the quarter that ended in Mar. 2018 was $0.32. Anthera Pharmaceuticals's Shares Outstanding (EOP) for the quarter that ended in Mar. 2018 was 26.18 Mil. Therefore, Anthera Pharmaceuticals's market cap for the quarter that ended in Mar. 2018 was $8.38 Mil.
Anthera Pharmaceuticals's quarterly market cap increased from Sep. 2017 ($16.37 Mil) to Dec. 2017 ($22.86 Mil) but then declined from Dec. 2017 ($22.86 Mil) to Mar. 2018 ($8.38 Mil).
Anthera Pharmaceuticals's annual market cap declined from Dec. 2015 ($185.62 Mil) to Dec. 2016 ($29.82 Mil) and declined from Dec. 2016 ($29.82 Mil) to Dec. 2017 ($22.86 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Anthera Pharmaceuticals's Enterprise Value for Today is $0.00 Mil.
The historical data trend for Anthera Pharmaceuticals's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthera Pharmaceuticals Annual Data | |||||||||||||||||||||
Trend | Dec08 | Dec09 | Dec10 | Dec11 | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | |||||||||||
Market Cap | Get a 7-Day Free Trial | 59.61 | 36.35 | 185.62 | 29.82 | 22.86 |
Anthera Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun13 | Sep13 | Dec13 | Mar14 | Jun14 | Sep14 | Dec14 | Mar15 | Jun15 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | |
Market Cap | Get a 7-Day Free Trial | 34.26 | 17.17 | 16.37 | 22.86 | 8.38 |
For the Biotechnology subindustry, Anthera Pharmaceuticals's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Anthera Pharmaceuticals's Market Cap distribution charts can be found below:
* The bar in red indicates where Anthera Pharmaceuticals's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Anthera Pharmaceuticals's Market Cap for the fiscal year that ended in Dec. 2017 is calculated as
Market Cap (A: Dec. 2017 ) | = | Share Price (A: Dec. 2017 ) | * | Shares Outstanding (EOP) (A: Dec. 2017 ) |
= | $1.65 | * | 13.8545 | |
= | $22.86 |
Anthera Pharmaceuticals's Market Cap for the quarter that ended in Mar. 2018 is calculated as
Market Cap (Q: Mar. 2018 ) | = | Share Price (Q: Mar. 2018 ) | * | Shares Outstanding (EOP) (Q: Mar. 2018 ) |
= | $0.32 | * | 26.1793 | |
= | $8.38 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anthera Pharmaceuticals (OTCPK:ANTH) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Thank you for viewing the detailed overview of Anthera Pharmaceuticals's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Christopher S Henney | director | 10505 ROSELLE STREET, SAN DIEGO CA 92121 |
Shanahan William R Jr | officer: Chief Medical Officer | 10301 STELLA LINK HOUSTON TX 77025 |
Brian Mueller | director | C/O BIOMARIN PHARMACEUTICAL INC., 105 DIGITAL DRIVE, NOVATO CA 94949 |
Paul F Truex | director | PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Charles V Olson | officer: Chief Technology Officer | 25801 INDUSTRIAL BLVD., SUITE B, HAYWARD CA 94545 |
Klara Dickinson | officer: Chief Regulatory Officer | C/O CYMABAY THERAPEUTICS, INC., 7575 GATEWAY BLVD., SUITE 110, NEWARK CA 94560 |
Steven B Engle | director | C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710 |
James Pennington | officer: Interim Chief Medical Officer | 25801 INDUSTRIAL BLVD, SUITE B, HAYWARD CA 94545 |
Hislop Colin | officer: Chief Medical Officer | C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502 |
Sanford S Zweifach | director | 21720 23RD DRIVE SE, SUITE 150, BOTHELL WA 98021 |
Daniel K Spiegelman | director | MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003 |
Christopher P. Lowe | officer: CFO and Chief Business Officer | 2511 N LOOP 1604,, SUITE 204, SAN ANTONIO TX 78258 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Orbimed Capital Gp Iv Llc | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
Samuel D Isaly | director | 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022 |
From GuruFocus
By Marketwired Marketwired • 06-27-2018
By gurufocus 10qk • 08-12-2010
By Julie Young • 11-08-2021
By gurufocus 10qk • 05-14-2010
By gurufocus 10qk • 11-12-2010
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.